Preexposure Prophylaxis for HIV Infection among African Women.


Van Damme, L; Corneli, A; Ahmed, K; Agot, K; Lombaard, J; Kapiga, S; Malahleha, M; Owino, F; Manongi, R; Onyango, J; Temu, L; Monedi, MC; Mak'oketch, P; Makanda, M; Reblin, I; Makatu, SE; Saylor, L; Kiernan, H; Kirkendale, S; Wong, C; Grant, R; Kashuba, A; Nanda, K; Mandala, J; Fransen, K; Deese, J; Crucitti, T; Mastro, TD; Taylor, D; the FEM-PrEP Study Group, ; (2012) Preexposure Prophylaxis for HIV Infection among African Women. The New England journal of medicine. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1202614

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (373kB) | Preview

Abstract

: Background Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. Methods In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily. The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. Results HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estimated hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P=0.81). The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P=0.04, P<0.001, and P=0.03, respectively). Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P=0.051). Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion. The study was stopped early, on April 18, 2011, because of lack of efficacy. Conclusions Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low. (Supported by the U.S. Agency for International Development and others; FEM-PrEP ClinicalTrials.gov number, NCT00625404 .).

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 22784040
Web of Science ID: 307001900006
URI: http://researchonline.lshtm.ac.uk/id/eprint/113672

Statistics


Download activity - last 12 months
Downloads since deposit
602Downloads
360Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item